<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consortium PSYCHIATRICUM</journal-id><journal-title-group><journal-title xml:lang="en">Consortium PSYCHIATRICUM</journal-title><trans-title-group xml:lang="ru"><trans-title>Consortium PSYCHIATRICUM</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2712-7672</issn><issn publication-format="electronic">2713-2919</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">9300</article-id><article-id pub-id-type="doi">10.17816/CP9300</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CASE REPORT</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The Use of Umbilical Cord Blood Nucleated Cells in the Treatment of Regressive Autism: A Case Report</article-title><trans-title-group xml:lang="ru"><trans-title>Применение ядросодержащих клеток пуповинной крови в лечении регрессивного аутизма: клинический случай</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9575-0749</contrib-id><name-alternatives><name xml:lang="en"><surname>Morozova</surname><given-names>Yana V.</given-names></name><name xml:lang="ru"><surname>Морозова</surname><given-names>Яна Вячеславовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Senior Researcher, Laboratory of Human Stem Cells</p></bio><bio xml:lang="ru"><p>к.м.н., cтарший научный сотрудник лаборатории стволовых клеток человека</p></bio><email>yanamorozova0@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5042-6534</contrib-id><name-alternatives><name xml:lang="en"><surname>Smirnov</surname><given-names>Vladimir N.</given-names></name><name xml:lang="ru"><surname>Смирнов</surname><given-names>Владимир Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Biol.), Academician of RAS; Leading Researcher, Laboratory of Human Stem Cells</p></bio><bio xml:lang="ru"><p>д.б.н., aкадемик РАН, руководитель лаборатории стволовых клеток человека</p></bio><email>yanamorozova0@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0176-3846</contrib-id><name-alternatives><name xml:lang="en"><surname>Makarov</surname><given-names>Igor V.</given-names></name><name xml:lang="ru"><surname>Макаров</surname><given-names>Игорь Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Head of the Department of Child Psychiatry; Professor of the Department of Psychiatry and Narcology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, заведующий отделением детской психиатрии; профессор кафедры психиатрии и наркологии </p></bio><email>yanamorozova0@gmail.com</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8189-1479</contrib-id><name-alternatives><name xml:lang="en"><surname>Emelina</surname><given-names>Darya A.</given-names></name><name xml:lang="ru"><surname>Емелина</surname><given-names>Дарья Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Researcher, Department of Child Psychiatry</p></bio><bio xml:lang="ru"><p>к.м.н., научный сотрудник отделения детской психиатрии</p></bio><email>yanamorozova0@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Medical Research Center of Cardiology</institution></aff><aff><institution xml:lang="ru">ФГБУ «НМИЦК им. ак. Е.И. Чазова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">North-Western State Medical University named after I.I. Mechnikov</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-09-24" publication-format="electronic"><day>24</day><month>09</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-12-22" publication-format="electronic"><day>22</day><month>12</month><year>2023</year></pub-date><volume>4</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>39</fpage><lpage>47</lpage><history><date date-type="received" iso-8601-date="2023-05-17"><day>17</day><month>05</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-09-07"><day>07</day><month>09</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Morozova Y.V., Smirnov V.N., Makarov I.V., Emelina D.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Морозова Я.В., Смирнов В.Н., Макаров И.В., Емелина Д.А.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Morozova Y.V., Smirnov V.N., Makarov I.V., Emelina D.A.</copyright-holder><copyright-holder xml:lang="ru">Морозова Я.В., Смирнов В.Н., Макаров И.В., Емелина Д.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consortium-psy.com/jour/article/view/9300">https://consortium-psy.com/jour/article/view/9300</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND: </bold>Interest in the issue of childhood autism has surged in the recent decades. At the same time, despite the significant progress achieved in understanding the etiological and pathogenetic aspects of the condition, effective ways to treat it have continued to elude us. Stem cell therapy appears to hold great promise in the treatment and rehabilitation of patients with both neurological diseases (cerebral palsy, hydrocephalus) and mental disorders (autism, schizophrenia).</p> <p><bold>METHODS: </bold>This article presents a case report describing the use of nucleated cord blood cells in a patient with regressive autism and resistance to standard therapies. The child’s condition was assessed before treatment and 6 and 12 months after.</p> <p><bold>RESULTS: </bold>Clinical observation, psychometric, and instrumental diagnostic methods led to a significant improvement in the child’s condition in the form of perception development, reduction of somatosensory disorders, normalization of emotional status, and a development of social and communication skills.</p> <p><bold>CONCLUSION:</bold> We assume that the result obtained may be associated with the normalization of the immunological status of our patient thanks to the cord blood cells therapy and consider it necessary to conduct further studies into the effectiveness of the method, taking the pathogenic mechanisms of autism into account.</p></abstract><trans-abstract xml:lang="ru"><p><bold>ВВЕДЕНИЕ: </bold>Последние десятилетия можно отметить усиление интереса к проблеме детского аутизма. При этом, несмотря на значительное продвижение в понимании этиологических и патогенетических аспектов, до сих пор не удалось найти эффективные способы лечения аутизма. Терапия стволовыми клетками показала большие перспективы в лечении и реабилитации пациентов как с неврологическими заболеваниями (ДЦП, гидроцефалия), так и с психическими расстройствами (аутизм, шизофрения).</p> <p><bold>МЕТОДЫ: </bold>В этой статье приводится клинический случай, описывающий применение ядросодержащих клеток пуповинной крови у пациента с регрессивной формой аутизма и резистентностью к стандартным методам терапии. Состояние ребенка оценивалось до лечения и через 6 и 12 месяцев.</p> <p><bold>РЕЗУЛЬТАТЫ: </bold>Клиническое наблюдение, психометрические и инструментальные методы диагностики позволили выявить выраженную положительную динамику в состоянии ребенка в виде развития восприятия, снижения соматосенсорных нарушений, нормализации эмоционального статуса, развития социализации и коммуникативных способностей.</p> <p><bold>ЗАКЛЮЧЕНИЕ: </bold>Мы предполагаем, что полученный результат может быть связан с нормализацией иммунологического статуса нашего пациента на фоне терапии клетками пуповинной крови и считаем необходимым проведение дальнейших исследований эффективности методики с учетом патогенетических механизмов развития аутизма.</p></trans-abstract><kwd-group xml:lang="en"><kwd>treatment</kwd><kwd>autism</kwd><kwd>cell therapy</kwd><kwd>children disorders</kwd><kwd>HUCBCs</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>лечение</kwd><kwd>аутизм</kwd><kwd>клеточная терапия</kwd><kwd>расстройства у детей</kwd><kwd>ядросодержащие клетки пуповинной крови</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Iles A. Autism Spectrum Disorders. Prim Care. 2021 Sep;48(3):461-73. doi: 10.1016/j.pop.2021.04.003.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Yin J, Schaaf CP. Autism genetics — an overview. PrenatDiagn. 2017;37(1):14-30. doi: 10.1002/pd.4942.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bhandari R, Paliwal JK, Kuhad A. Neuropsychopathology of autism spectrum disorder: complex interplay of genetic, epigenetic, and environmental factors. Adv Neurobiol. 2020;24:97–141. doi: 10.1007/978-3-030-30402-7_4.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Thapar A, Rutter M. Genetic advances in autism. J Autism Dev Disord. 2021;51(12):4321–32. doi: 10.1007/s10803-020-04685-z.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Goel R, Hong JS, Findling RL, Ji NY. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry. 2018;30(1):78–95. doi: 10.1080/09540261.2018.1458706.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Persico AM, Ricciardello A, Cucinotta F. The psychopharmacology of autism spectrum disorder and Rett syndrome. Handbook of clinical neurology. 2019;165:391–414. doi: 10.1016/B978-0-444-64012-3.00024-1.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Shmakova OP. Structural and dynamic features of early disability due to mental diseases. Pulse. 2020;22(10):62–7 (2020). doi: 10.26787/nydha-2686-6838-2020-22-10-62-67. Russian.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Donegan JJ, Lodge DJ. Stem cells for improving the treatment of neurodevelopmental disorders. Stem Cells Dev. 2020;29(17):1118–30. doi: 10.1089/scd.2019.0265.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Larijani B, ParhizkarRoudsari P, Hadavandkhani M, Alavi-Moghadam S, Rezaei-Tavirani M, Goodarzi P, Sayahpour FA, Mohamadi-Jahani F, Arjmand B. Stem cell-based models and therapies: a key approach into schizophrenia treatment. Cell Tissue Bank. 2021;22(2):207–23. doi: 10.1007/s10561-020-09888-3.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Sun JM, Song AW, Case LE, Mikati MA, Gustafson KE, Simmons R, Goldstein R, Petry J, McLaughlin C, Waters-Pick B, Chen LW, Wease S, Blackwell B, Worley G, Troy J, Kurtzberg J. Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: a randomized, placebo-controlled trial. Stem Cells Trans Med. 2017;6(12):2071–8. doi: 10.1002/sctm.17-0102.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Romanov YA, Tarakanov OP, Radaev SM, Dugina TN, Ryaskina SS, Darevskaya AN, Morozova YV, Khachatryan WA, Lebedev KE, Zotova NS, Burkova AS, Sukhikh GT, Smirnov VN. Human allogeneic AB0/Rh-identical umbilical cord blood cells in the treatment of juvenile patients with cerebral palsy. Cytotherapy. 2015;17(7):969–78. doi: 10.1016/j.jcyt.2015.02.010.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Surugiu R, Olaru A, Hermann DM, Glavan D, Catalin B, Popa-Wagner A. Recent advances in mono- and combined stem cell therapies of stroke in animal models and humans. Int J Mol Sci. 2019;20(23):6029. doi: 10.3390/ijms20236029.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Peng X, Song J, Li B, Zhu C, Wang X. Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges. J Neurosci Res. 2020;98(5):815-825. doi: 10.1002/jnr.24548.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Wang SM, Lee CU, Lim HK. Stem cell therapies for Alzheimer’s disease: is it time? Curr Opin Psychiatry. 2019;32(2):105–16. doi: 10.1097/YCO.0000000000000478.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ternovoy S, Ustyuzhanin D, Morozova Y, Shariya M, Roldan-Valadez E, Smirnov V. Functional MRI evince the safety and efficacy of umbilical cord blood cells therapy in patients with schizophrenia. Schizophr Res. 2020;224:175–7. doi: 10.1016/j.schres.2020.09.028.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Morozova YV, Radaev SM, Voronova EI, Emelina DA. Umbilical cord blood cells in the treatment of patients with schizophrenia in remission. Genes &amp; Cells. 2021;16(1):75–81. doi: 10.23868/202104012. Russian.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lv YT, Zhang Y, Liu M, Qiuwaxi JN, Ashwood P, Cho SC, Huan Y, Ge RC, Chen XW, Wang ZJ, Kim BJ, Hu X. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med. 2013;11:196. doi: 10.1186/1479-5876-11-196.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Murias M, Major S, Compton S, Buttinger J, Sun JM, Kurtzberg J, Dawson G. Electrophysiological biomarkers predict clinical improvement in an ppen-label trial assessing efficacy of autologous umbilical cord blood for treatment of autism. Stem Cells Transl Med. 2018;7(11):783-791. doi: 10.1002/sctm.18-0090.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Chez M, Lepage C, Parise C, Dang-Chu A, Hankins A, Carroll M. Safety and observations from a placebo-controlled, crossover study to assess use of autologous umbilical cord blood stem cells to improve symptoms in children with autism. Stem Cells Transl Med. 2018;7(4):333-341. doi: 10.1002/sctm.17-0042.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Rubinstein P, Dobrila L, Rosenfield RE, Adamson JW, Migliaccio G, Migliaccio AR, Taylor PE, Stevens CE. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA. 1995 Oct 24;92(22):10119-22. doi: 10.1073/pnas.92.22.10119.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996 Jun;5(3):213-26. doi: 10.1089/scd.1.1996.5.213.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Pranke P, Hendrikx J, Alespeiti G, Nardi N, Rubinstein P, Visser J. Comparative quantification of umbilical cord blood CD34+ and CD34+ bright cells using the ProCount-BD and ISHAGE protocols. Braz J Med Biol Res. 2006;39(7):901–6. doi: 10.1590/s0100-879x2006000700008.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Mayes SD. Brief report: checklist for autism spectrum disorder: most discriminating items for diagnosing autism. J Autism Dev Disord. 2018;48(3):935–9. doi: 10.1007/s10803-017-3401-0.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Mahapatra S, Vyshedsky D, Martinez S, Kannel B, Braverman J, Edelson SM, Vyshedskiy A. Autism Treatment Evaluation Checklist (ATEC) norms: a “Growth Chart” for ATEC score changes as a function of age. Children (Basel). 2018;5(2):25. doi: 10.3390/children5020025.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Panasyuk AY. [Adapted version of D. Wexler’s method (WISC)]. Moscow: Institute of Hygiene for Children and Adolescents of the Ministry of Health of the USSR; 1973. p. 80. Russian.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Eggermont JJ. Auditory brainstem response. Handb Clin Neurol. 2019;160:451–64. doi: 10.1016/B978-0-444-64032-1.00030-8.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Maric DM, Papic V, Radomir M, Stanojevic I, Sokolovac I, Milosavljevic K, Maric DL, Abazovic D. Autism treatment with stem cells: a case report. Eur Rev Med Pharmacol Sci. 2020;24(15):8075–80. doi: 10.26355/eurrev_202008_22491.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Shroff G. Human embryonic stem cells in the treatment of autism: a case series. InnovClinNeurosci. 2017;14(3-4):12–6.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Kobinia GS, Zaknun JJ, Pabinger C, Laky B. Case report: autologous bone marrow derived intrathecal stem cell transplant for autistic children - a report of four cases and literature review. Front Pediatr. 2021;9:620188. doi: 10.3389/fped.2021.620188.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Okur SÇ, Erdoğan S, Demir CS, Günel G, Karaöz E. The effect of umbilical cord-derived mesenchymal stem cell transplantation in a patient with cerebral palsy: a case report. Int J Stem Cells. 2018;11(1):141–7. doi: 10.15283/ijsc17077.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Zhang C, Huang L, Gu J, Zhou X. Therapy for cerebral palsy by human umbilical cord blood mesenchymal stem cells transplantation combined with basic rehabilitation treatment: a case report. Glob Pediatr Health. 2015;2:2333794X15574091. doi: 10.1177/2333794X15574091.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Prosperi M, Guiducci L, Peroni DG, Narducci C, Gaggini M, Calderoni S, Tancredi R, Morales MA, Gastaldelli A, Muratori F, Santocchi E. Inflammatory biomarkers are correlated with some forms of regressive autism spectrum disorder. Brain Sci. 2019;9(12):366. doi: 10.3390/brainsci9120366.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Liberman AC, Trias E, da Silva Chagas L, Trindade P, Dos Santos Pereira M, Refojo D, Hedin-Pereira C, Serfaty CA. Neuroimmune and inflammatory signals in complex disorders of the central nervous system. Neuroimmunomodulation. 2018;25(5-6):246–70. doi: 10.1159/000494761.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Prem S, Millonig JH, DiCicco-Bloom E. Dysregulation of neurite outgrowth and cell migration in autism and other neurodevelopmental disorders. AdvNeurobiol. 2020;25:109–53. doi: 10.1007/978-3-030-45493-7_5.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Donovan AP, Basson MA. The neuroanatomy of autism — a developmental perspective. J Anat. 2017;230(1):4–15. doi: 10.1111/joa.12542.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Tamouza R, Fernell E, Eriksson MA, Anderlid BM, Manier C, Mariaselvam CM, Boukouaci W, Leboyer M, Gillberg C. HLA Polymorphism in regressive and non-regressive autism: a preliminary study. Autism Res. 2020;13(2):182-186. doi: 10.1002/aur.2217.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Enstrom A, Onore C, Tarver A, Hertz-Picciotto I, Hansen R, Croen L, Van de Water J, Ashwood P. Peripheral blood leukocyte production of BDNF following mitogen stimulation in early onset and regressive autism. Am J BiochemBiotechnol. 2008;4(2):121–29. doi: 10.3844/ajbbsp.2008.121.129.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Malek M, Ashraf-Ganjouei A, Moradi K, Bagheri S, Mohammadi MR, Akhondzadeh S. Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial. ClinNeuropharmacol. 2020;43(2):39–45. doi: 10.1097/WNF.0000000000000382.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Golla S, Sweeney JA. Corticosteroid therapy in regressive autism: preliminary findings from a retrospective study. BMC Med. 2014;12:79. doi: 10.1186/1741-7015-12-79.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2020;53(1):e12712. doi: 10.1111/cpr.12712.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Luque-Campos N, Contreras-López RA, Jose Paredes-Martínez M, Torres MJ, Bahraoui S, Wei M, Espinoza F, Djouad F, Elizondo-Vega RJ, Luz-Crawford P. Mesenchymal stem cells improve rheumatoid arthritis progression by controlling memory T cell response. Front Immunol. 2019;10:798. doi: 10.3389/fimmu.2019.00798.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Damien P, Allan DS. Regenerative therapy and immune modulation using umbilical cord blood-derived cells. Biol Blood Marrow Transplant. 2015;21(9):1545–54. doi: 10.1016/j.bbmt.2015.05.022.</mixed-citation></ref></ref-list></back></article>
